Elekta Receives Jury Ruling in U.S. Patent Dispute.Business, Legal and Medical Editors STOCKHOLM, Sweden--(BW HealthWire)--Feb. 27, 2002 A jury in the United States District Court United States District Court In the U.S., any of the 94 trial courts of general jurisdiction in the federal judicial system. Each state, as well as the District of Columbia and the Commonwealth of Puerto Rico, has at least one federal district court. in California has entered a verdict against certain companies in the Elekta Group (STHLM STHLM Stockholm :EKTA.B) in the amount of approximately USD USD In currencies, this is the abbreviation for the U.S. Dollar. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 17 million based on a finding of patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. . Elekta intends to appeal the judgment of the District Court based on this verdict to the United States Court of Appeal for the Federal Circuit, the appellate court with nationwide jurisdiction in patent cases. Elekta's opinion, supported by legal counsel in the case, is that the appeal will have a strong basis. Elekta estimates that a potential final judgment for damages would be covered by an insurance facility for liability-related situations, such as patent infringement and product liability. Elekta previously disclosed information about this dispute in its prospectus for the new issue in 1999 and in the 2000/2001 Annual Report. Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery neurosurgery /neu·ro·sur·gery/ (noor´o-sur?jer-e) surgery of the nervous system. neu·ro·sur·ger·y n. Surgery on any part of the nervous system. solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective, cost efficient and gentle to the patient. For further information, contact: Hakan Bergstrom, CFO See Chief Financial Officer. , Elekta AB (publ), +46 8 587 255 47 Tomas Puusepp, President, Elekta Instruments Inc., 770/300-9725 Patrick Lyon, Taylor Rafferty, Investor Relations, 212/889-4350 For more information about Elekta, visit www.elekta.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion